| Secondary |
| Diabetes Mellitus |
15.3% |
| Drug Use For Unknown Indication |
7.1% |
| Insomnia |
7.1% |
| Neuropathy Peripheral |
7.1% |
| Pain |
7.1% |
| Asthma |
5.9% |
| Diabetic Neuropathy |
5.9% |
| Type 2 Diabetes Mellitus |
5.9% |
| Constipation |
4.7% |
| Gastritis |
4.7% |
| Ovarian Cancer |
4.7% |
| Diabetes Mellitus Non-insulin-dependent |
3.5% |
| Hypertension |
3.5% |
| Prophylaxis Against Gastrointestinal Ulcer |
3.5% |
| Atrial Fibrillation |
2.4% |
| Breast Cancer |
2.4% |
| Cardiovascular Insufficiency |
2.4% |
| Depression |
2.4% |
| Insulin-requiring Type 2 Diabetes Mellitus |
2.4% |
| Pain In Extremity |
2.4% |
|
| Hepatic Function Abnormal |
13.6% |
| Hypothermia |
13.6% |
| Cervical Myelopathy |
9.1% |
| Loss Of Consciousness |
9.1% |
| Visual Acuity Reduced |
9.1% |
| Convulsion |
4.5% |
| Drug-induced Liver Injury |
4.5% |
| Interstitial Lung Disease |
4.5% |
| Neuropathy Peripheral |
4.5% |
| Overdose |
4.5% |
| Rhabdomyolysis |
4.5% |
| Staphylococcal Infection |
4.5% |
| Staphylococcal Sepsis |
4.5% |
| Tonic Convulsion |
4.5% |
| Urine Ketone Body |
4.5% |
|
| Concomitant |
| Hypertension |
19.7% |
| Diabetes Mellitus |
14.6% |
| Type 2 Diabetes Mellitus |
11.3% |
| Diabetic Neuropathy |
8.0% |
| Product Used For Unknown Indication |
6.4% |
| Drug Use For Unknown Indication |
4.7% |
| Hyperlipidaemia |
3.9% |
| Prostate Cancer Stage Iv |
3.9% |
| Constipation |
3.8% |
| Hepatitis C |
3.6% |
| Insomnia |
3.3% |
| Neuropathy Peripheral |
2.5% |
| Gastritis |
2.4% |
| Prophylaxis |
2.1% |
| Pain |
1.9% |
| Benign Prostatic Hyperplasia |
1.8% |
| Cardiovascular Disorder |
1.6% |
| Angina Pectoris |
1.6% |
| Nephrotic Syndrome |
1.6% |
| Cerebral Infarction |
1.5% |
|
| Hypoglycaemia |
11.9% |
| Renal Impairment |
8.8% |
| Liver Disorder |
7.5% |
| Vomiting |
7.5% |
| Hepatic Function Abnormal |
6.9% |
| Interstitial Lung Disease |
6.3% |
| Hypotension |
5.0% |
| Prostate Cancer |
5.0% |
| Dizziness |
4.4% |
| Pancytopenia |
3.8% |
| Sepsis |
3.8% |
| Somnolence |
3.8% |
| Suicide Attempt |
3.8% |
| Upper Gastrointestinal Haemorrhage |
3.8% |
| Fatigue |
3.1% |
| Pyrexia |
3.1% |
| Rhabdomyolysis |
3.1% |
| Vith Nerve Paralysis |
3.1% |
| Atrioventricular Block Complete |
2.5% |
| Death |
2.5% |
|
| Interacting |
| Product Used For Unknown Indication |
94.4% |
| Onychomycosis |
5.6% |
|
| Drug Interaction |
50.0% |
| Condition Aggravated |
25.0% |
| Dementia |
25.0% |
|
